Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kindler appointed Pfizer chairman

Executive Summary

Pfizer CEO Jeffrey Kindler replaces Hank McKinnell as chairman of the firm's board of directors, effective Dec. 19. The appointment is a vote of confidence in Kindler as the company looks to regain traction following the termination of development of its headline pipeline candidate torcetrapib/atorvastatin (1"The Pink Sheet" Dec. 11, 2006, p. 3). McKinnell, who resigned from the chief executive post in July, was slated to give up the chairman position in February 2007 (2"The Pink Sheet" Aug. 7, 2006, p. 3). Pfizer says McKinnell will step down from the board when he leaves the company in February...

You may also be interested in...



Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program

Pfizer Set For “Fundamental And Sustained” Change Under New CEO Kindler

Newly appointed CEO Jeffrey Kindler appears to be laying the groundwork for significant changes in Pfizer's strategic direction

Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.

Latest News
See All
UsernamePublicRestriction

Register

PS047872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel